Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy.
Gueiderikh A, Baude J, Baron D, Schiappa R, Katsahian S, Moreau D, Laurans M, Bibault JE, Kreps S, Bondiau PY, Quivrin M, Lépinoy A, Pasquier D, Hannoun-Levi JM, Giraud P. Gueiderikh A, et al. Among authors: schiappa r. Front Oncol. 2024 Oct 25;14:1468248. doi: 10.3389/fonc.2024.1468248. eCollection 2024. Front Oncol. 2024. PMID: 39525616 Free PMC article.
Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: A multicenter retrospective analysis.
Baron D, Pasquier D, Pace-Loscos T, Vandendorpe B, Schiappa R, Ortholan C, Hannoun-Levi JM. Baron D, et al. Among authors: schiappa r. Clin Transl Radiat Oncol. 2023 Dec 8;45:100710. doi: 10.1016/j.ctro.2023.100710. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2023. PMID: 38179575 Free PMC article.
Response to "Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients - A closer inspection will improve your vision".
Baron D, Pasquier D, Pace-Loscos T, Vandendorpe B, Schiappa R, Ortholan C, Hannoun-Levi JM. Baron D, et al. Among authors: schiappa r. Clin Transl Radiat Oncol. 2024 Feb 21;46:100755. doi: 10.1016/j.ctro.2024.100755. eCollection 2024 May. Clin Transl Radiat Oncol. 2024. PMID: 38440793 Free PMC article. No abstract available.
Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.
Benezery K, Montagne L, Evesque L, Schiappa R, Hannoun-Levi JM, Francois E, Thamphya B, Gerard JP. Benezery K, et al. Among authors: schiappa r. Clin Transl Radiat Oncol. 2020 Jul 6;24:92-98. doi: 10.1016/j.ctro.2020.07.001. eCollection 2020 Sep. Clin Transl Radiat Oncol. 2020. PMID: 32695890 Free PMC article.
Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group.
Ka K, Schiappa R, Terlizzi M, Mallet F, Martin E, Chand ME, Demogeot N, Peiffert D, Pommier P, Quivrin M, Kissel M, Pasquier C, Khalifa J, Bossi A, Hannoun-Levi JM, Blanchard P. Ka K, et al. Among authors: schiappa r. Radiother Oncol. 2023 Mar;180:109460. doi: 10.1016/j.radonc.2022.109460. Epub 2023 Jan 10. Radiother Oncol. 2023. PMID: 36638842
101 results